Submitted by Jean Medeiros (jeanletras@uepb.edu.br) on 2016-09-29T13:44:49Z No. of bitstreams: 1 PDF - Palas Atenéia Dantas de Medeiros.pdf: 2158304 bytes, checksum: bf27754a7517b804bb7e707c432b84ad (MD5) / Approved for entry into archive by Secta BC (secta.csu.bc@uepb.edu.br) on 2016-10-05T16:59:28Z (GMT) No. of bitstreams: 1 PDF - Palas Atenéia Dantas de Medeiros.pdf: 2158304 bytes, checksum: bf27754a7517b804bb7e707c432b84ad (MD5) / Made available in DSpace on 2016-10-05T16:59:28Z (GMT). No. of bitstreams: 1 PDF - Palas Atenéia Dantas de Medeiros.pdf: 2158304 bytes, checksum: bf27754a7517b804bb7e707c432b84ad (MD5) Previous issue date: 2014-08-27 / Proeac/Proapex - UEPB / Introduction: This study characterized the profile of patients treated at the “Alcides Carneiro” University Hospital (HUAC), users of phenobarbital in order to support actions of therapeutic drug monitoring. Methods: Fifty patients were interviewed using a standardized questionnaire. Results: It was observed that 50% of patients have been using the drug for a long time (7.68 years on average). About 74% of respondents are under monotherapy and 59.5% of these have their seizures controlled. The patients under monotherapy have more chance of success in controlling seizures. The main anticonvulsant drug combination observed was phenobarbital with carbamazepine (66% of patients). Sedation and dizziness are among the main adverse effects, reported by 34% of patients. Monotherapy seems to be a protective factor only for adverse effect dizziness (OR=3.1). Conclusions: The analysis of these and other results presented in this paper may be useful in promoting rational use of anticonvulsants at the HUAC. / Este trabalho caracteriza o perfil clínico e epidemiológico dos pacientes atendidos no Hospital Universitário Alcides Carneiro (HUAC), que usam fenobarbital como anticonvulsivante, a fim de subsidiar ações de monitorização terapêutica. Entrevistou-se 50 pacientes, de 2011 a 2012, mediante um questionário padronizado. Observou-se que, 74% dos entrevistados estão sob monoterapia e 59,5% destes possuem suas crises controladas. Nos pacientes sob politerapia (26%) o índice de controle das crises é de 23,07%. É possível afirmar que pacientes sob monoterapia têm mais chance de sucesso no controle das crises convulsivas (Odds Ratio = 4,400). A principal associação anticonvulsivante observada foi do fenobarbital com a carbamazepina (66%). Entre os efeitos adversos relatados destacam-se a sedação e a tontura (34% dos pacientes). A monoterapia parece se constituir como fator de proteção apenas para o efeito adverso tontura (OR de 3,1). Esses resultados poderão ser úteis na promoção do uso racional de anticonvulsivantes no HUAC.